The pharma service provider EffRx Pharmaceuticals is one of the founding members of the World Orphan Drug Alliance (WODA) alongside a number of other companies. According to a press release, WODA will seek to support pharmaceutical and biotech companies with a portfolio for rare diseases, oncology and highly specialized therapeutics. In addition to EffRx Pharmaceuticals, the companies Medis, Orpharm, OrphanDC and Vector Pharma are all involved in WODA.
According to its website, EffRx Pharmaceuticals, based in Freienbach in the canton of Schwyz, focuses on the development and marketing of prescription drugs for niche and orphan indications, i.e. indications for rare diseases. EffRx is seeking in-licensing opportunities in Europe in niche therapeutic areas, with a focus on rare diseases for which one of the products in the pipeline has received orphan drug designation (ODD) status from the U.S. Food and Drug Administration (FDA). At present, the company’s lead product is Binosto, which is a drug for the treatment of osteoporosis.
The EffRx press release states that WODA covers 68 countries in the following regions: Turkey, the Middle East and North Africa, Russia and the CIS (Commonwealth of Independent States) region, Central and Eastern Europe, Latin America and Switzerland.
Headquartered in Slovenia, Medis is a marketing partner for pharmaceutical and biotech companies in Central and Eastern Europe. The Moscow-based Orpharm covers Russia and the CIS. OrphanDC is headquartered in the Brazilian city of São Paulo and operates as a partner for biotech companies in Latin America. Vector Pharma is a Dubai-based full-service distribution service provider that operates across the Middle East, North Africa and Turkey.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space